Exercise appears to have context-dependent effects. Regular physical activity is generally associated with better intestinal function and systemic health, whereas prolonged or poorly individualized high-intensity exercise may impair gastrointestinal integrity. The mechanisms identified in the review include splanchnic hypoperfusion, increased intestinal permeability and oxidative stress; prolonged intense activity may also cause transient changes in the gut microbial community. These effects can compromise gastrointestinal performance in athletes. The review therefore emphasizes the intensity and individualization of activity, but the supplied evidence does not establish a specific timing protocol or a single exercise regimen for people with celiac disease.

Diet acts through nutrient intake, symptom control and the microbial environment, making its relationship with exercise and immunity especially relevant in celiac disease. A Mediterranean-style gluten-free diet appears to improve nutritional adequacy and musculoskeletal health in the evidence summarized by the review. For selected individuals who adhere to a strict gluten-free diet but continue to experience irritable bowel syndrome-like symptoms, a short-term low-FODMAP diet may provide symptom relief. That finding concerns persistent gastrointestinal symptoms rather than demonstrated improvement of celiac disease itself, and the review does not establish a universal diet for children or athletes. Nutritional adequacy, gastrointestinal tolerance and gluten-free requirements must instead be considered together when assessing dietary strategies.

Children with celiac disease offer a clinically relevant setting for examining these interactions because physical activity, dietary management, growth and skeletal development converge during development. The review reports that integrating individualized activity with optimized dietary management supports growth, skeletal development and long-term health, including among physically active children and young athletes. It also positions celiac disease as a model for studying how lifestyle factors affect intestinal physiology, immune regulation and microbial communities. As a review, however, its conclusions depend on heterogeneous evidence involving different populations, activity patterns, diets and microbiome profiles; it does not demonstrate that one combined intervention produces a uniform benefit. The central conclusion is that individualized exercise and nutritional optimization may improve gastrointestinal function, musculoskeletal health and quality of life, while excessive training or nutritional imbalance can undermine those outcomes.

Subject of Research: Clinical review of exercise, diet and gut microbiota in children and athletes with celiac disease

Article Title: Interactions between physical activity, diet, and gut microbiota in gastrointestinal health: celiac disease as a model in children and athletes

Article References: Montano, A., Paolini, A., Felli, C., Bruno, S. P., Baldassarre, A., Sandal, S., & Masotti, A. (2026). Interactions between physical activity, diet, and gut microbiota in gastrointestinal health: celiac disease as a model in children and athletes. Frontiers in Sports and Active Living, 8, Article 1940762. https://doi.org/10.3389/fspor.2026.1940762

Image Credits: AI Generated

DOI: 10.3389/fspor.2026.1940762

Keywords: celiac disease, physical activity, gut microbiota, gastrointestinal health, children, athletes, gluten-free diet, low-FODMAP diet, bone health, immune regulation, Interactions, between

The research team searched PubMed, Web of Science, and the Cochrane Library from their inception to 6 February 2026, with additional searches of Scopus and Embase conducted on 17 August 2026. After screening more than 1,300 records, they identified 22 study reports representing 17 unique trials — 15 randomised and 2 non-randomised controlled trials — encompassing 588 unique participants. The clinical populations spanned hypertension, prediabetes, type 1 and type 2 diabetes, breast cancer, prostate cancer, and broader metabolic risk profiles. Participants ranged in age from roughly 14 to 67 years, and interventions ran from 8 weeks to 12 months, typically delivered two to three times per week at moderate-to-vigorous intensity, with net playing time between 7 and 45 minutes per session.

Methodologically, the analysis was more sophisticated than most in this field. Because some trials contributed multiple effect estimates — through multiple intervention arms, linked reports from the same cohort, or repeated measures of the same outcome — the authors used three-level random-effects meta-analyses that treated effect sizes as nested within trials. They then applied cluster-robust (CR2) variance estimation, clustering on the independent trial, to every outcome as a robustness check, and drew conclusions only where the two inferential procedures agreed. Certainty of evidence was rated with the GRADE framework, and prediction intervals were reported to show how variable the true effects might be across different settings.

The headline findings are striking for a group of patients often excluded from vigorous team sport. Recreational football was associated with significant improvements in cardiorespiratory fitness, with a standardised mean difference (SMD) of 0.70 for peak oxygen uptake (VO₂peak) and an even larger 1.43 for Yo-Yo Intermittent Endurance Test performance. Cardiovascular outcomes also improved: diastolic blood pressure fell (SMD −0.53), mean arterial pressure dropped (SMD −0.89), and resting heart rate showed the largest effect in the entire synthesis (SMD −1.01). In clinically interpretable units, the pooled mean differences amounted to roughly a 5 mmHg reduction in mean arterial pressure and a 5.7 beats-per-minute reduction in resting heart rate.

Body composition and blood lipids moved in the right direction too. Body fat percentage declined significantly (SMD −0.36), muscle mass increased modestly (SMD 0.22), and both triglycerides (SMD −0.56) and total cholesterol (SMD −0.69) fell. Notably, body weight, BMI, and waist circumference did not change significantly — a pattern the authors attribute to the insensitivity of scale-based measures to compositional change when fat is lost and lean tissue is gained, particularly in patients taking medications with weight-active effects. One prostate cancer trial, for example, reported a between-group lean body mass difference of about 0.7 kilograms after 12 weeks of football training in men undergoing androgen deprivation therapy.

The bone-health results tell a subtler story. Plasma osteocalcin, a marker of bone formation, rose significantly (SMD 1.07), and P1NP, another formation marker, increased under the primary analysis (SMD 1.28). Yet DXA-derived bone mineral density and content showed no significant changes, and the P1NP effect did not survive cluster-robust inference. The authors interpret this as evidence of early anabolic signalling in response to the mechanical loading of football — the jumps, turns, accelerations, and decelerations that small-sided games demand — without enough training exposure to produce measurable structural remodelling in older, clinically vulnerable cohorts. Bone turnover markers can respond within weeks, whereas density changes typically require longer and are most visible at mechanically loaded lower-limb sites.

Several seemingly positive findings proved fragile under scrutiny. Borderline effects on fat mass, systolic blood pressure, and LDL cholesterol were not retained under cluster-robust inference, and effects on body fat percentage, fat mass, muscle mass, systolic pressure, and LDL were sensitive to the assumed pre–post correlation used to derive change-score statistics. No significant pooled effects emerged for HbA1c, fasting glucose, fasting insulin, HDL cholesterol, or C-reactive protein. Across 27 outcomes, the statistical interpretation was unchanged for 22 under the robust procedure — but certainty of evidence was rated low to very low for most outcomes, and prediction intervals for several significant findings crossed zero, meaning the average benefit was not reproduced consistently across diagnoses and programmes.

On feasibility, the picture is encouraging but not uniform. Mean attendance across 13 independent trials was 82.7 percent, and mean attrition across 14 trials was 15.6 percent — respectable figures for exercise interventions in clinical populations, and consistent with the idea that the social structure, team affiliation, and sheer enjoyment of football help sustain engagement where solitary treadmill work often fails. Adverse events were summarised narratively because quantitative pooling was impossible: most reported events were musculoskeletal, including muscle soreness, strains, joint pain, and lower-limb injuries, with occasional serious injuries such as fibular fractures and Achilles tendon ruptures. Several trials noted that injuries clustered in the early phase of training, underscoring the importance of progressive exposure, warm-up, and qualified supervision.

The authors are explicit that these results should not be read as evidence that football can replace established exercise prescriptions or as a disease-specific therapy. The included populations differ enormously in pathophysiology, treatment burden, medication status, and baseline fitness, and the number of studies within any single diagnostic category was too small for firm conclusions. In hypertension, blood-pressure effects were inconsistent, particularly among patients already on antihypertensive medication, where residual headroom for further lowering may be limited. In diabetes, glycaemic outcomes were largely unchanged at the pooled level, plausibly because fasting indices and HbA1c are relatively insensitive to modest exercise effects in pharmacologically controlled patients. Cancer-related evidence came from small, highly selected samples with variable attendance.

Nevertheless, the synthesis marks a milestone for the ‘Football is Medicine’ platform, which has argued for years that small-sided games deliver a uniquely multimodal stimulus — cardiovascular, neuromuscular, and osteogenic load within a single session — that continuous aerobic training and isolated resistance exercise cannot match. The physiological profile is coherent: heart rates of 80 to 90 percent of maximum, repeated high-intensity efforts, and weight-bearing impacts together explain the concurrent gains in fitness, heart rate, body fat, and bone formation markers. For appropriately screened patients who prefer group-based, game-based activity and can participate safely under supervision, the authors conclude that recreational football may be considered a supervised adjunctive exercise option — particularly where cardiorespiratory fitness is the target. Adequately powered, diagnosis-specific trials with standardised reporting of training dose, adherence, and adverse events are the next step before football earns a formal place in the clinical exercise toolkit.

Subject of Research: Effects and feasibility of recreational football exercise in patients with chronic diseases

Article Title: Recreational football as medicine? A meta-analysis of its effects and feasibility in patients with chronic diseases

Article References: Wei, K., Chen, G., Wang, T., & Wang, B. (2026). Recreational football as medicine? A meta-analysis of its effects and feasibility in patients with chronic diseases. Frontiers in Public Health, 14, Article 1869982. https://doi.org/10.3389/fpubh.2026.1869982

Image Credits: AI Generated

DOI: 10.3389/fpubh.2026.1869982

Keywords: recreational football, meta-analysis, chronic disease, cardiorespiratory fitness, blood pressure, hypertension, type 2 diabetes, cancer survivors, bone health, exercise as medicine, body composition, feasibility

Congenital adrenal hyperplasia is a group of autosomal recessive disorders of adrenal steroidogenesis in which impaired cortisol synthesis triggers chronic overdrive of the hypothalamic-pituitary-adrenal axis and variable excess or deficiency of adrenal androgens. The 21-hydroxylase deficiency form accounts for 90 to 95 percent of cases worldwide, with rarer enzymatic defects such as 11β-hydroxylase deficiency and 17α-hydroxylase/17,20-lyase deficiency making up the remainder, each with its own hormonal fingerprint and growth trajectory. Managing the disease means walking a pharmacological tightrope: enough glucocorticoid to replace cortisol and suppress adrenocorticotropic hormone-driven steroid excess, but not so much that the drug itself poisons growth, puberty, metabolism and bone. Neonatal screening and multidisciplinary care have transformed survival and quality of life, shifting clinical attention toward the long-term comorbidities that now define the adult lives of these patients.

Glucocorticoids are among the most bone-hostile drugs in medicine. They increase bone resorption and suppress bone formation, degrading microarchitecture and raising fracture risk. Their effects extend to calcium handling: by antagonizing vitamin D signaling in the gut they reduce intestinal calcium absorption, while increasing renal calcium excretion, producing a negative calcium balance that triggers compensatory parathyroid hormone elevation — secondary hyperparathyroidism. That mechanism is particularly damaging during adolescence, when optimal calcium retention is essential for peak bone mass acquisition. In congenital adrenal hyperplasia the skeletal impact depends on cumulative exposure, treatment duration and the supraphysiologic dosing often needed to rein in androgen excess. Androgens, meanwhile, have anabolic effects by stimulating osteoblast proliferation, so androgen excess may partially compensate for glucocorticoid-related bone loss — but chronic supraphysiologic androgen levels also accelerate bone maturation, advance bone age and shorten the bone accrual window, limiting the net benefit.

The review’s most striking technical point concerns how bone density is measured and interpreted. Most pediatric and adolescent studies have relied on dual-energy x-ray absorptiometry, which reports areal bone mineral density as Z-scores relative to chronological age. But in congenital adrenal hyperplasia, chronological age and bone age frequently diverge. Garcia Alves Junior and colleagues found that Z-scores appear normal or even elevated when interpreted by chronological age, yet are significantly reduced when normalized for bone age — revealing a true impairment in bone accrual masked by accelerated skeletal maturation. In other words, the fast-growing skeletons of these teenagers look deceptively dense simply because they are older, biologically, than their birthdays. Cross-sectional studies comparing adolescents with Tanner-matched controls add site-specific nuance: lumbar spine bone density was significantly reduced, whereas femoral density was less consistently affected, and daily glucocorticoid dose showed a negative association with bone parameters while higher androgen exposure correlated positively, hinting at partial anabolic compensation.

Longitudinal data sharpen the concern that puberty is not the rescue window clinicians might hope for. In a cohort followed from pubertal onset to adult height, treatment with gonadotropin-releasing hormone agonists — sometimes used to slow precocious puberty and prolong skeletal growth — did not adversely affect bone density outcomes. But Z-scores declined over time across multiple skeletal sites in both treated and untreated patients, indicating progressive divergence from reference populations during late adolescence and early adulthood. Similarly, a marked decline in whole-body and lumbar spine Z-scores from prepuberty to adulthood, particularly in males, has been observed, with deficits becoming more evident after puberty completed. Taken together, these studies suggest that puberty does not constitute a window for recovery of skeletal deficits in congenital adrenal hyperplasia; rather, sustained glucocorticoid exposure and an altered sex steroid milieu may progressively limit the acquisition of peak bone mass.

Beyond drug dose and hormones, body composition has emerged as a third determinant of skeletal fate. Ryabets-Lienhard and colleagues reported an inverse association between lumbar spine height-adjusted bone density Z-scores and total, visceral and subcutaneous fat mass, independent of glucocorticoid dose, suggesting that excess adiposity exerts a direct detrimental effect on bone accrual during puberty. Bone dynamics are also coming into view: higher glucocorticoid doses and the use of prednisolone were associated with reduced annual lumbar spine accrual compared with hydrocortisone therapy, and bone turnover markers adjusted for bone age — particularly C-terminal telopeptide, a resorption marker — independently predicted subsequent bone density accrual. That finding opens the possibility of dynamic biomarker monitoring during adolescence, moving beyond static scans. Vitamin D insufficiency, frequently reported in pediatric patients with the disease, may represent a further modifiable contributor to impaired skeletal mineralization during this critical window.

The rarer enzymatic defects offer a natural experiment in how the sex steroid milieu shapes the adolescent skeleton. In 11β-hydroxylase deficiency, cortisol deficiency combines with mineralocorticoid precursor excess — causing hypertension — and pronounced hyperandrogenism. The skeletal phenotype reflects chronic androgen excess during childhood: advanced bone age, accelerated growth, early or precocious puberty and premature epiphyseal closure. Yet the evidence is largely auxological and radiological; densitometric and microarchitectural data in adolescents are scarce, and fracture risk is essentially unknown. In stark contrast, 17α-hydroxylase/17,20-lyase deficiency produces profound hypoandrogenism and hypoestrogenism, resulting in delayed bone age, absent pubertal growth spurt and delayed epiphyseal closure. Limited high-resolution imaging studies suggest reduced cortical and trabecular volumetric density, cortical thinning and increased porosity — but adolescent-specific longitudinal data and fracture assessments are lacking. Other rare defects, including PORD mutations, STAR deficiency and HSD3B2 deficiency, combine variable degrees of cortisol and sex steroid deficiency, sometimes with congenital skeletal malformations, and evidence on their skeletal health is essentially absent.

Perhaps the most sobering message concerns bone quality rather than quantity. Direct data on microarchitecture and fracture risk in adolescents are lacking, but studies in adult populations using high-resolution peripheral quantitative computed tomography demonstrate cortical thinning and trabecular deterioration even in individuals with normal DXA-derived density. Epidemiological and registry-based cohorts, including the dsd-LIFE study, indicate increased fracture prevalence, often manifesting in early adulthood. These observations strongly suggest that qualitative skeletal deficits originate during childhood and adolescence, remaining subclinical until later life. The absence of fractures during adolescence, the review warns, should not be interpreted as evidence of preserved bone strength. Non-classic forms of 21-hydroxylase deficiency, with partial enzyme impairment and milder or intermittent glucocorticoid therapy, appear to fare better — older studies report fewer fractures than in severe forms, though recent adult data are conflicting and no bone turnover marker data exist for this subgroup.

The clinical implications are concrete. During adolescence, hydrocortisone is preferred for its shorter half-life and flexibility, allowing dose adjustments during growth and bone development — though puberty increases hydrocortisone clearance, complicating disease control and demanding careful monitoring. Excess dosing above 17 mg/m²/day should be avoided, since it is inversely associated with final height and bone mass, and long-acting glucocorticoids are generally reserved for post-growth phases due to higher skeletal risk. Modified-release hydrocortisone offers more physiological 24-hour cortisol profiles and may better suppress the morning androgen surge, but adolescent experience remains limited. Annual bone age assessment is essential to interpret density measurements in adolescents with advanced skeletal maturation, with DXA ideally interpreted using bone age- and height-adjusted references, and high-resolution imaging reserved for high-risk research cases. Adequate calcium intake, routine vitamin D monitoring and regular weight-bearing physical activity are modifiable levers that partially counteract glucocorticoid-related skeletal effects, while sedentary behavior and increased adiposity impair accrual.

The transition from pediatric to adult care coincides with the final stages of peak bone mass acquisition and represents a vulnerable phase: discontinuity of care, reduced adherence and shifts in treatment goals from growth optimization to metabolic and reproductive health can all undermine hormonal control. Glucocorticoid regimens are often modified during transition, sometimes introducing longer-acting compounds that increase cumulative exposure if not carefully titrated, while persistent hyperandrogenism or excessive androgen suppression from overtreatment can both impair bone accrual. Structured transition programs with coordinated pediatric and adult endocrine care and standardized assessment of bone density and pubertal status are therefore essential. The Padova team calls for longitudinal, phenotype-specific studies incorporating advanced imaging to better define fracture risk and guide evidence-based management across the lifespan. For now, the message for clinicians and families is clear: the skeletons of teenagers with congenital adrenal hyperplasia may look fine on a standard scan while quietly falling behind — and puberty alone will not close the gap.

Subject of Research: Bone health in adolescents with congenital adrenal hyperplasia: exploring the interplay between glucocorticoid therapy, hormonal imbalance and puberty

Article Title: Bone health in adolescents with congenital adrenal hyperplasia: exploring the interplay between glucocorticoid therapy, hormonal imbalance and puberty

Article References: Tizianel, I., Ceccato, F., & Barbot, M. (2026). Bone health in adolescents with congenital adrenal hyperplasia: exploring the interplay between glucocorticoid therapy, hormonal imbalance and puberty. Frontiers in Adolescent Medicine, 4, Article 1827315. https://doi.org/10.3389/fradm.2026.1827315

Image Credits: AI Generated

DOI: 10.3389/fradm.2026.1827315

Keywords: congenital adrenal hyperplasia, bone health, glucocorticoids, puberty, peak bone mass, adolescent endocrinology, bone mineral density, 21-hydroxylase deficiency, Bone, health, adolescents, congenital

The paper, authored by researchers at the University of Illinois Chicago, the University of Chicago, and the University of Miami Health System, proposes a lifespan framework for women’s health in sickle cell disease that stretches from menarche through menopause and into healthy aging. Its central claim is provocative: while fertility and pregnancy have received increasing attention as patients survive longer, menopause remains an underexplored and underrecognized phase of the disease trajectory, one that may shape pain, cognition, bone strength, cardiovascular risk, iron burden, and quality of life for decades.

To understand why menopause matters so much in this population, it helps to revisit the biology. Sickle cell disease stems from a single nucleotide substitution in the beta-globin gene that produces hemoglobin S. Under low-oxygen conditions, this hemoglobin polymerizes, forcing red blood cells into rigid, crescent shapes. These sickled cells are less deformable, stick to the vascular endothelium, and clog small vessels, producing the hallmark vaso-occlusive pain crises. Repeated sickling also damages cell membranes, driving chronic hemolysis, which in turn depletes nitric oxide, fuels oxidative stress, and sustains endothelial dysfunction and inflammation. The result is a multisystem disorder in which overlapping mechanisms inflict cumulative organ injury beginning in childhood.

That cumulative injury has led some researchers to describe sickle cell disease as a form of accelerated biological aging. The lungs are vulnerable to acute chest syndrome, pulmonary embolism, and pulmonary hypertension. Kidney damage can begin with tubular dysfunction in childhood and progress to chronic kidney disease in adolescence and adulthood. Cerebrovascular injury, from silent cerebral infarction to overt stroke, erodes cognition and quality of life. Against this backdrop, the authors argue, reproductive aging is not a separate process but another manifestation of aging that deserves a place alongside the rest.

Female physiology adds further layers of complexity. Although the disease arises from a single mutation, its severity is modified by genetics, including variants regulating fetal hemoglobin such as those affecting BCL11A, co-inherited alpha-thalassemia, APOL1 kidney risk variants, and pathways involved in oxidative stress and inflammation. Environmental exposures such as air pollution, secondhand smoke, and psychosocial stress worsen outcomes. And female-specific states modulate disease directly: menstruation can precipitate vaso-occlusive pain episodes beginning at menarche, hormonal fluctuations across the cycle influence vascular tone and inflammatory balance, hormonal contraceptives may alter thrombotic risk, and pregnancy, with its increased oxygen demand and prothrombotic state, amplifies the underlying vasculopathy.

Historically, clinical attention to reproduction in sickle cell disease has clustered around two moments: preserving fertility and managing pregnancy. Both matter. Hypoxic-ischemic injury, chronic inflammation, and gonadal exposure to disease-modifying therapies or transplant conditioning can diminish ovarian reserve. Pregnancy carries heightened risks of vaso-occlusive complications, acute chest syndrome, thromboembolism, preeclampsia, and medically indicated preterm delivery, and treatment decisions during pregnancy remain hampered by gaps in evidence. But the authors contend that this framing treats reproductive health as a series of isolated episodes rather than a continuous life course, and that the continuum does not end with pregnancy. It transitions into midlife, where the evidence is thinnest.

What evidence exists suggests that menopause arrives early. A Brazilian cohort reported menopause roughly five years earlier than expected in the general population, at approximately 46 to 48 years of age, and more recent observational studies from U.S. cohorts have similarly reported mean ages in the mid-to-late forties. These findings come with heavy caveats: small samples, single-center designs, and retrospective data collection that invites recall bias. Larger prospective studies are needed to determine whether reproductive aging is consistently accelerated, and whether timing differs by genotype, disease severity, or treatment exposure. Still, the signal is strong enough that the authors argue menopause should be treated as a critical component of comprehensive sickle cell care.

The midlife picture is more complicated than a simple worsening. In one cohort, up to 80 percent of women reported a reduction in vaso-occlusive pain frequency after menopause, raising the possibility that hormonal changes influence pain pathways, though the authors caution this should not be read as evidence that menopause consistently improves disease-related pain. Meanwhile, vasomotor symptoms, sleep disturbance, mood changes, anxiety, and fatigue may emerge or intensify during the transition, and because many of these overlap with core manifestations of sickle cell disease, menopause-related morbidity risks being misattributed entirely to the underlying condition, leading to underdiagnosis and undertreatment.

Treatment raises its own unresolved questions. Menopausal hormone therapy is the most effective treatment for vasomotor symptoms and has established indications for women with premature or early menopause, but there are currently no adequately powered clinical trials evaluating its safety, efficacy, or optimal formulation and duration in women with sickle cell disease. Because the disease is characterized by endothelial dysfunction, inflammation, and a prothrombotic state, thrombosis is an obvious concern, yet the authors stress that whether hormone therapy adds clinically meaningful thrombotic risk in this population has not been established; it is an important clinical question, not a demonstrated contraindication. Genitourinary syndrome of menopause, with its vaginal dryness, dyspareunia, and urinary symptoms, is another likely under-recognized burden, and low-dose vaginal estrogen, which has minimal systemic absorption, has not been evaluated in these patients.

Beyond symptoms, menopause may intersect with organ systems already compromised by the disease. Estrogen decline accelerates bone resorption, compounding skeletal vulnerability from chronic inflammation, marrow hyperplasia, vitamin D deficiency, and delayed puberty. Cessation of menstruation eliminates a physiologic route of iron loss, and emerging observations suggest iron indices may rise after menopause even after accounting for transfusion history, a particular concern for women with transfusion exposure. Cognitive health presents perhaps the most striking intersection: women with sickle cell disease may enter the menopausal transition carrying pre-existing neurovascular vulnerability from chronic anemia, cerebral hypoxia, and silent infarcts, so midlife hormonal changes unfold under far higher neurological risk than in the general population. Frailty and functional decline, the authors hypothesize, may likewise accelerate when menopause-related changes land on decades of disease-related physiologic stress.

The equity dimensions are hard to ignore. Sickle cell disease disproportionately affects populations in sub-Saharan Africa, the Middle East, India, and parts of the Americas, precisely the regions where access to comprehensive chronic disease management, reproductive health services, and menopause care is most variable. Even in resource-rich settings, care is fragmented between hematology, obstetrics, gynecology, and primary care; menopause may fall outside hematologists’ traditional scope, while menopause clinicians may have little experience with the disease. In low- and middle-income settings, structured menopause care may be entirely absent from routine services, meaning women enter midlife without any systematic assessment of symptoms or surveillance for bone, cardiovascular, cognitive, and functional decline.

The authors’ prescription is a coordinated lifespan model: routine screening for menstrual changes, vasomotor symptoms, sleep, mood, fatigue, genitourinary symptoms, and sexual health as women approach midlife; careful attribution of new or changing symptoms to both disease and menopause rather than defaulting to the disease alone; individualized hormone therapy decisions weighing genotype, prior venous thromboembolism, and vascular risk; and referral pathways connecting sickle cell specialists with menopause expertise. They also call for research priorities spanning prospective cohorts tracking age at menopause, genotype-stratified analyses, trials of menopause therapies, cognitive and neuroimaging studies, and implementation research adapted to local resources rather than assuming one multidisciplinary model fits all settings.

The stakes extend beyond any single clinic. As survival improves, the measure of success for a lifelong genetic disease can no longer be simply keeping children alive; it must be whether those children grow into adults who age well. Integrating reproductive aging into clinical practice, research agendas, and health policy, the authors argue, is an opportunity to strengthen women-centered care and advance health equity for the millions of women worldwide living with sickle cell disease. Menopause, long invisible in the sickle cell literature, may turn out to be one of the most consequential frontiers in the field.

Subject of Research: Menopause and reproductive aging in women with sickle cell disease across the lifespan

Article Title: From menarche to menopause: a lifespan perspective on women's health in sickle cell disease

Article References: Farooqui, M., Christmas, M., Goba, G., & Hsu, L. (2026). From menarche to menopause: a lifespan perspective on women's health in sickle cell disease. Frontiers in Epidemiology, 6, Article 1931488. https://doi.org/10.3389/fepid.2026.1931488

Image Credits: AI Generated

DOI: 10.3389/fepid.2026.1931488

Keywords: sickle cell disease, menopause, women's health, reproductive aging, menopausal hormone therapy, vaso-occlusive pain, health equity, bone health, cognitive health, iron overload, cardiovascular risk, lifespan care

The review, led by Pierre Philippe Wilson Registe of the Université de Sherbrooke and colleagues in Canada, is the first comprehensive update in nearly two decades. The last major systematic review on this topic, published by Hallal and colleagues in 2006, covered articles from 2000 to 2004 and documented weak to moderate associations between adolescent physical activity and adult physical activity, breast cancer risk, bone health, and cardiovascular risk factors. It did not touch mental health, quality of life, or general health at all. Since then, a surge of cohort studies has generated new knowledge about how teenage exercise relates to future well-being, and the new review pulls that scattered evidence into a single, coherent picture.

To do so, the team searched five major databases — AMED, Medline, CINAHL, APA PsycINFO, and Embase — using keywords representing five concepts: physical activity, adolescence, health status, early adulthood, and longitudinal design. They considered only articles in English or French, included participants aged 12 to 29 years, and required studies to measure the association between physical activity during adolescence and health markers in early adulthood. Of 5,188 articles identified, 44 met the inclusion criteria. The studies were conducted in the Americas (23), Europe (17), and Oceania (4), with publication years spanning 2002 to 2024. None were judged to be of low quality; 25 were rated moderate and 19 good on the McMaster University critical appraisal tool.

The review’s most striking finding concerns the persistence of exercise behavior itself. Sixteen of the 18 studies that assessed whether physical activity levels or participation track from adolescence into early adulthood supported a positive association — though the strength was low to moderate, with correlations below 0.3. In practical terms, an active teenager is more likely to be an active young adult, but the relationship is far from deterministic. Seven of the 18 articles reported mixed positive-null findings, meaning the association held for some measures but not others. Notably, two Finnish studies found that active transportation in adolescence — walking or cycling to school — was unrelated to device-measured physical activity levels in early adulthood, making it the only type of teenage exercise that showed no long-term link to adult activity levels.

Physical health outcomes told a similarly nuanced story. Of 17 studies examining physical health, 11 found a positive relationship and 6 found no association. Bone health emerged as a particularly robust benefit: four studies found that physically active adolescents had better bone mineral density, bone size, content, and strength in early adulthood, particularly at the hip and proximal femur. One UK study found that moderate-to-vigorous physical activity during adolescence, but not light-intensity activity, was positively associated with hip bone mineral density measured by dual-energy x-ray absorptiometry at age 25 for both sexes. Body mass index was the most studied cardiovascular risk factor, and six studies supported that active adolescents have lower BMI in early adulthood compared to inactive peers. Interestingly, all four studies that examined blood pressure found no association — a null result the authors attribute to the strong cardiovascular homeostatic mechanisms of young adults, whose blood pressure levels were within normal ranges with little variance, making any exercise effect difficult to detect.

Mental health may be where the review carries its greatest public health weight. Of 18 studies using mental health outcomes, 16 suggested that physical activity in adolescence is beneficial to mental health in early adulthood. Eleven articles studied depression or depressive symptoms, and ten of them showed adolescent physical activity was protective. Team sport involvement appeared protective in one study while individual sport involvement did not, and two studies found the association only for boys, not girls. Anxiety was measured in six articles, with team sport participation emerging as a protective factor in two of four studies focused on that domain. Four articles examined stress, with two finding that school sports participation or high physical activity levels in adolescence were related to lower stress in early adulthood. Two further studies showed that longer team sports participation and higher physical activity levels during adolescence were associated with better positive mental health in young adults.

The authors propose the behavioral tracking hypothesis as a primary explanation for these long-term effects. Active adolescents are more likely to remain active later in life and to develop healthier behaviors, which supports health benefits throughout life. The review supports this by showing that sports participation and physical activity levels in adolescence track to a low-to-moderate extent into early adulthood, suggesting that part of the exercise habits acquired in adolescence persist through the transition to adulthood. It is possible that physical activity tracked from adolescence to early adulthood because of habit formation and because exercise is socially patterned — the social interactions and networks developed through physical activity during adolescence may continue to influence behaviors in future years. For mental health specifically, the effect of adolescent physical activity on young adult well-being seemed to be mediated by factors such as self-esteem, self-efficacy, and emotional and social skills developed through exercise.

Quality of life and general health rounded out the picture. Only three studies examined adolescent physical activity and quality of life in early adulthood, with two reporting positive associations — one 8-year study found that fulfilling the WHO physical activity recommendation was positively associated with health-related quality of life, and a 13-year study found that later adolescence physical activity was a strong predictor of future quality of life. In contrast, a study with a longer follow-up found no association. General health was more consistent: in all five studies that assessed this relationship, more physical activity in adolescence was associated with better general health in early adulthood, regardless of whether the exposure was measured as sports participation, physical activity level, or specific activities.

The review is not without limitations. A meta-analysis was not feasible due to substantial heterogeneity among the included studies — variations in definitions of physical activity during adolescence, developmental periods assessed, and measurement approaches for the same outcomes in young adulthood. As an alternative, the team used a vote counting approach based on the direction of effect within each study, classifying associations as positive, negative, null, or mixed. Several studies adjusted for potential confounders, but residual confounding remains a concern: socioeconomic status, parental education, family environment, and co-occurring health behaviors such as diet, smoking, and alcohol use are closely linked to both physical activity participation during adolescence and health outcomes in adulthood, and inconsistent adjustment for these factors may partly explain the generally small observed associations. The majority of studies also relied on self-report measures, which are prone to recall and social desirability bias, and none used compositional data analysis to capture the composite nature of physical activity, a recommendation of the 2030 Global Action Plan. Generalizability may be limited as well, since most studies were conducted in the United States, Europe, and Oceania, and the review was restricted to English and French publications.

Still, the overall message is clear and consistent. With the exception of active transportation, participating in most types of physical activity during adolescence appears to confer small but beneficial effects across health outcomes in the future — higher physical activity levels, fewer mental health issues, better bone mineral density, lower BMI, fewer cardiovascular risk factors, and better general health. The associations were generally in the same direction among boys and girls, suggesting the relationships are broadly consistent across sexes. The authors conclude that the results support the potential importance of promoting physical activity throughout adolescence for health in early adulthood. In an era when teenage exercise is dropping for most individuals during the transition to adulthood, the evidence suggests that the investment made in those formative years may pay dividends well beyond the teenage decade itself.

Subject of Research: Health

Article Title: Long-term associations between physical activity during adolescence and health in early adulthood: a systematic review

Article References: Registe, P. P. W., Black, S., Gallant, F., Tanguay, P., Saucier, D., Faivre, P., Mekari, S., & Bélanger, M. (2026). Long-term associations between physical activity during adolescence and health in early adulthood: a systematic review. Frontiers in Adolescent Medicine, 4, Article 1808570. https://doi.org/10.3389/fradm.2026.1808570

Image Credits: AI Generated

DOI: 10.3389/fradm.2026.1808570

Keywords: physical activity, adolescence, mental health, systematic review, public health, bone health, longitudinal studies, Long-term, associations, between, physical, activity

The research, published in Frontiers in Urology by a team led by Manuela Montatore and Giuseppe Guglielmi across the Universities of Foggia and hospitals in Brindisi, Bisceglie, and Barletti, examined 40 men who started ADT at Antonio Perrino Hospital in Brindisi between January 2023 and May 2025. Every patient had a contrast-enhanced CT scan within 30 days before treatment began and a technically comparable follow-up scan roughly a year later. Instead of ordering new imaging, the team extracted quantitative body-composition data from these existing oncologic examinations, an approach known as opportunistic imaging. The results paint a striking picture of simultaneous deterioration across three tissue compartments that conventional clinical measures largely missed.

The technical logic of the study rests on a well-validated principle of quantitative radiology: a single axial CT section at the third lumbar vertebra (L3) serves as a reliable surrogate for whole-body tissue composition. Using semiautomated threshold-based segmentation with attenuation windows of −29 to +150 Hounsfield units for muscle, −190 to −30 HU for subcutaneous fat, and −150 to −50 HU for visceral fat, the researchers measured the skeletal muscle index (SMI), bilateral psoas muscle attenuation, the subcutaneous adipose tissue index (SATI), and the visceral adipose tissue index (VATI). They then extended the analysis into the skeleton itself, placing oval regions of interest within the trabecular bone of the L1 to L3 vertebral bodies to capture vertebral attenuation, an opportunistic marker of bone health that no prior longitudinal ADT study has combined with muscle and fat in the same imaging framework.

After approximately twelve months of androgen suppression, the changes were substantial and consistent. Mean skeletal muscle index fell from 48.4 to 45.5 cm²/m², a relative decline of 6.0 percent. Mean psoas attenuation, which reflects the radiodensity of muscle tissue and indirectly captures fatty infiltration, dropped from 41.0 to 37.8 HU, a 7.8 percent reduction. Subcutaneous fat increased by 11.6 percent and visceral fat by 6.2 percent, while mean vertebral trabecular attenuation declined by 4.4 percent, from 132.1 to 126.3 HU, suggesting concurrent loss of bone quality. Twenty-three of the forty patients, or 57.5 percent, lost at least 5 percent of their skeletal muscle index, a prespecified exploratory threshold. All of these changes reached statistical significance, with p-values ranging from 0.018 to below 0.001.

What makes these findings especially compelling is what did not change: body mass index. BMI rose only modestly, from 26.7 to 27.0 kg/m², a difference that was not statistically significant, and the correlation between BMI change and SMI change was weak and nonsignificant (Spearman ρ = 0.24). The most telling statistic concerns the 23 men with clinically meaningful muscle loss: fifteen of them, or 65.2 percent, had a stable or increased BMI over the same period. Fat gain had effectively masked muscle depletion on the scale. This adiposity-driven camouflage means that a clinician relying on weight or BMI alone could wrongly conclude that a patient is tolerating treatment well, even as his metabolic reserve and physical resilience erode beneath a stable surface.

The study also explored whether any baseline feature could predict who would suffer the steepest muscle decline. In a deliberately parsimonious three-variable logistic regression model restricted to age, baseline psoas attenuation, and metastatic status, lower baseline psoas attenuation emerged as the only factor associated with a 5 percent or greater SMI decline, with an odds ratio of 1.14 per 1-HU decrease. Patients who ultimately lost the most muscle had started with noticeably darker, more fat-infiltrated muscle on their initial scans, averaging 38.9 HU compared with 43.8 HU in those with smaller declines. The authors are careful to frame this as hypothesis-generating: with only 40 patients, the model cannot establish psoas attenuation as an independent predictive biomarker, but it raises the possibility that a single number extracted from a pre-treatment scan could one day flag men at highest risk before therapy begins.

Why should androgen deprivation remodel muscle, fat, and bone simultaneously? Testosterone is an anabolic hormone that supports protein synthesis in skeletal muscle and suppresses adipogenesis. When it is pharmacologically eliminated, muscle catabolism accelerates, fat accumulates preferentially in visceral depots, and the delicate coupling between muscle and skeleton weakens. These compartments are not independent silos; they communicate through mechanical loading, hormonal signaling, inflammatory pathways, and metabolic crosstalk. A growing body of evidence links these tissue changes to hard clinical outcomes. Previous work has associated skeletal muscle loss during ADT with increased non-cancer mortality in high-risk prostate cancer, and more recent longitudinal studies have connected ADT-induced muscle loss and fat gain to subsequent cardiovascular events, suggesting that body composition may be a barometer of whole-patient vulnerability beyond oncologic status alone.

The reproducibility data strengthen the case that these measurements are robust rather than artifacts of measurement technique. When a second blinded radiologist independently re-analyzed ten patients’ paired scans, interobserver agreement was excellent: intraclass correlation coefficients reached 0.97 for SMI, 0.94 for psoas attenuation, 0.98 for SATI, 0.97 for VATI, and 0.93 for vertebral trabecular attenuation. The team also enforced strict technical comparability, requiring all paired scans to use the same portal venous contrast phase, matched tube voltage (120 kVp in 87.5 percent of pairs), and similar reconstruction thickness, because enhancement phase and acquisition parameters can shift attenuation values and contaminate longitudinal comparisons. Vertebral analysis proved feasible in 92.5 percent of potentially assessable vertebral levels, with metastatic involvement, compression deformities, or artifacts accounting for the few exclusions.

Important caveats temper the enthusiasm. The study was retrospective, single-center, and small, and it lacked an untreated comparator group, so the observed remodeling cannot be attributed exclusively to ADT. Aging, cancer progression, chemotherapy, radiotherapy, androgen-receptor pathway inhibitors, comorbidities such as diabetes and cardiovascular disease, and lifestyle factors may all have contributed. The five deaths recorded during follow-up were far too few for any survival inference, and the vertebral attenuation values from contrast-enhanced scans were explicitly not treated as DXA-equivalent bone mineral density or as diagnostic of osteoporosis. Patients who died before the follow-up scan could not contribute to the paired analysis, introducing potential survival bias. The authors emphasize that the study demonstrates feasibility, not proven clinical benefit, and that no treatment decisions should yet be triggered by these measurements.

Even so, the implications are provocative. CT scans are among the most common examinations in oncology, acquired routinely for staging, surveillance, and treatment assessment, and every one of them contains quantitative information about muscle, fat, and bone that currently goes unused. If larger, prospective, controlled studies confirm that integrated CT-derived phenotyping predicts fractures, metabolic complications, cardiovascular risk, or survival during ADT, then the humble staging scan could evolve into a longitudinal body-composition monitoring tool requiring no additional radiation, cost, or patient burden. For the millions of men worldwide who depend on androgen suppression to keep their cancer in check, the study suggests a future in which the price of treatment is measured not just in tumor control, but in the health of every tissue it touches, visible in images doctors already possess.

Subject of Research: CT-derived body composition changes during androgen deprivation therapy for prostate cancer

Article Title: Longitudinal CT-derived muscle–fat–bone remodeling following androgen deprivation therapy initiation in prostate cancer

Article References: Montatore, M., Muscatella, G., Masino, F., Muscogiuri, E., & Guglielmi, G. (2026). Longitudinal CT-derived muscle–fat–bone remodeling following androgen deprivation therapy initiation in prostate cancer. Frontiers in Urology, 6, Article 1985221. https://doi.org/10.3389/fruro.2026.1985221

Image Credits: AI Generated

DOI: 10.3389/fruro.2026.1985221

Keywords: androgen deprivation therapy, prostate cancer, computed tomography, body composition, skeletal muscle index, sarcopenia, visceral adiposity, vertebral trabecular attenuation, opportunistic imaging, bone health, BMI, oncology

The scale of the analysis is what sets the study apart. The research team, led by Dr. Glen Pridham and Yoav Hayut from Alon’s lab in Weizmann’s Molecular Cell Biology Department, drew on two enormous datasets: results from the US National Health and Nutrition Examination Survey, collected over more than two decades, and medical records spanning roughly 20 years from Clalit, Israel’s largest health insurer. Datasets of this size are rarely brought to bear on menopause research, and the reason is simple: they usually lack the one piece of information that matters most for this kind of analysis, namely the age at which each woman had her final period.

That missing information creates a fundamental problem for anyone trying to pin down what happens at menopause itself. If women reach menopause at different ages, and a researcher aligns their medical records by calendar age, the true signal of the transition gets smeared across time. A sharp change that occurs at age 51 in one woman and age 54 in another looks, in the averaged data, like a gradual change stretched over several years. The apparent slowness of menopause, in other words, could partly be an artifact of the way the data are pooled rather than a property of the biology itself.

To cut through this blur, the Weizmann team borrowed an idea from an unexpected field: astronomy. Astronomers routinely sharpen images distorted by the optics of their telescopes by mathematically correcting for those distortions, a process known as deconvolution. The researchers developed a computational method inspired by this approach that removed the blurring introduced by differences in the age at which women reach menopause. Once that correction was applied, what emerged from the data was not a gentle slope but a distinct physiological turning point, a sudden shift in dozens of bodily measures concentrated around the time of the last menstrual period.

The breadth of the changes came as a surprise. Of the 90 types of laboratory tests examined, 52 showed abrupt changes at the transition, covering nearly all body systems. The affected measures included markers of bone health, liver function, kidney function, and cholesterol levels, alongside the expected shifts in sex hormones. This suggests that menopause is not confined to the reproductive axis but registers across the organism, with the end of ovarian hormone production rippling outward into metabolism, skeletal maintenance, and organ function in a coordinated and comparatively rapid way.

Two comparison groups in the data helped sharpen the interpretation. No such abrupt changes were observed in men of similar ages, indicating that the turning point is specific to the female transition rather than a general feature of aging in midlife. And among women receiving menopausal hormone therapy, the changes were less pronounced, a pattern consistent with the idea that the declining hormone levels themselves drive much of the body-wide shift. While the study’s design does not by itself establish hormone therapy as protective, the contrast offers a natural experiment hinting that supplementing the hormones lost at menopause may soften the physiological transition.

The timing of the underlying hormonal changes also proved more dramatic than expected. The sudden shifts at menopause were preceded by accelerating changes in sex hormone levels that began more than a decade before the final period, several years earlier than previous research had suggested. In practical terms, the body appears to enter a period of accelerating hormonal change in the mid-to-late thirties or early forties for many women, long before the first obvious symptoms of the transition appear. The final event at menopause, on this view, is the endpoint of a long buildup rather than the beginning of the story.

Because most of the abrupt changes identified in the study are associated with increased disease risk, the findings carry a clear message for preventive medicine. Bone loss, adverse changes in cholesterol, and declining kidney and liver measures are all modifiable risk factors, and interventions such as exercise and dietary improvement are most effective when they start early. Our study extends the window for potential preventive care to almost a decade before menopause, Alon says. That reframing turns the decade before the last period from a quiet prelude into a critical window in which women and their physicians can act on measurable, trackable changes in blood tests.

The methodological contribution may prove as consequential as the biological one. The deconvolution-style approach the team developed is not specific to menopause; it can, in principle, be applied to any large medical dataset in which a key event happens at different ages for different people, allowing researchers to recover the true sharpness of the underlying transition. More broadly, the method we developed may help study other major changes in life, such as puberty, pregnancy or the onset of disease, Alon notes. If other life transitions that look gradual in population data turn out to be sharp once the blur is removed, the study could reshape how medicine thinks about aging and disease onset more generally.

The study also involved Dr. Noa Lavi-Shoseyov and Prof. Michal Neeman of Weizmann’s Immunology and Regenerative Biology Department, Dr. Noa Hovav of the Menopause Community Center at Clalit Health Care, and Dr. Yoel Toledano of the Helen Schneider Women’s Hospital at Rabin Medical Center, with Dr. Lavi-Shoseyov additionally affiliated with the IVF Unit in the Department of Obstetrics and Gynecology at Kaplan Medical Center. Taken together, the work recasts menopause as a discrete physiological event with a long and measurable runway leading up to it. For the more than one million women whose records made the discovery possible, and for the millions more approaching the transition, the practical takeaway is that the years before menopause matter far more than has been assumed, and that routine laboratory tests, viewed through the right computational lens, can reveal a turning point in time to act on it.

Subject of Research: A computational analysis of large medical datasets revealing a sudden body-wide physiological transition at menopause

Article Title: Menopause: more than a slow change, it’s a sudden shift across the body

Article References: Menopause: more than a slow change, it’s a sudden shift across the body. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: menopause, Weizmann Institute, Nature Medicine, deconvolution, sex hormones, preventive medicine, bone health, cholesterol, hormone therapy, NHANES, Clalit, biomarkers

The scale of the undertaking sets this study apart. Drawing on the Million Women Study, a cohort recruited between 1996 and 2001 through NHS breast screening centres across England and Scotland, the research team tracked participants through electronic hospital records until the end of 2023. Over an average of 19.7 years of follow-up, 27,318 women suffered an incident hip fracture, providing the statistical power that earlier studies—often limited to a few hundred cases—could only dream of. Hip fracture is a major public health burden in ageing societies: nearly 72,000 such fractures occurred among people aged 60 and over in England, Wales and Northern Ireland in 2025, more than 80 percent of cases occur in people aged 75 and older, and hospitalisation costs the UK around £2 billion per year. Women bear the brunt, with a female-to-male ratio of roughly 2.5 to 1 among people aged 50 and above.

The methodological approach, known as a diet-wide association study or DWAS, is designed to counter a long-standing weakness of nutritional epidemiology. Historically, researchers have tested one or two dietary factors at a time—calcium, vitamin D, dairy—leaving most of the diet unexplored and inviting cherry-picked findings. By modelling all 99 factors with a consistent, prespecified analytical framework, the Oxford team could compare foods and nutrients on equal footing and correct for multiple testing using the Benjamini-Hochberg false discovery rate method. Dietary intake was captured with a validated 130-item food frequency questionnaire administered around 2001, and then calibrated against a 24-hour web-based dietary recall completed by a subset of participants roughly a decade later, a technique that reduces regression dilution bias—the attenuation of true associations caused by everyday measurement error in self-reported diets.

The statistical machinery was correspondingly rigorous. Cox proportional hazards regression, with attained age as the underlying time scale, estimated hazard ratios for each dietary factor, stratified by birth year, questionnaire year and region of residence. Covariate selection was guided by a directed acyclic graph, and models progressed through three levels of adjustment: from basic demographics and deprivation, through lifestyle factors such as smoking, alcohol, exercise and menopausal hormone therapy, to body mass index. Women with previous hip fractures, implausibly low or high energy intakes, or diet changes due to illness were excluded, and follow-up before age 55 was excluded for women not yet clearly postmenopausal. Sensitivity analyses excluded the first five years of follow-up to guard against reverse causation—the possibility that pre-existing poor health drives both eating habits and fracture risk.

The headline results are striking. Among foods, chicken showed the strongest inverse association, with each additional 20 grams per day linked to a 16 percent lower risk of hip fracture. Vegetables followed, with a 12 percent lower risk per 100 grams per day, and pasta with a 13 percent lower risk per 20 grams per day. At the other end of the spectrum, chips carried a 14 percent higher risk per 25 grams per day, and fizzy drinks an 18 percent higher risk per 50 grams per day. Among nutrients, protein led the protective list at a 21 percent lower risk per 15 grams per day, followed by zinc at 19 percent lower per 2 milligrams, niacin at 18 percent lower per 10 milligrams, fibre at 11 percent lower per 5 grams, and carotene at 9 percent lower per 1,000 micrograms. Only three nutrients were positively associated: retinol, free sugars and saturated fatty acids.

Many of these associations had never been reported before. Of the top five foods and top five nutrients, only six had appeared in previous prospective studies, meaning the DWAS identified 35 novel associations alongside confirming 25 previously reported ones. The chicken finding is particularly novel—no prior prospective cohort study had specifically examined chicken in relation to hip fracture. Similarly, zinc, potassium and selenium had never before been investigated for this outcome. The protein result aligns with a recent meta-analysis of four cohort studies reporting substantially lower fracture risk at higher intakes, and the vegetable finding mirrors a pooled analysis showing an inverse association for highest versus lowest consumption.

Biology offers several plausible mechanisms for these patterns. Protein is a structural component of the collagen matrix that gives bone its flexibility, and both protein and fibre intake are positively associated with insulin-like growth factor-1, a hormone that directly stimulates osteoblasts, the cells that build bone. Magnesium participates in vitamin D activation and bone mineralisation. Vegetables and fruits supply antioxidants that observational and intervention studies link to lower oxidative stress, a process implicated in age-related bone loss. Protein also helps preserve muscle mass and strength, which in turn maintain bone mineral density and reduce the risk of falls—the proximate trigger of most hip fractures in older women.

Yet the researchers are emphatic that these observational associations should not be read as causal prescriptions. A recurring pattern in the data raises the spectre of residual confounding: foods considered healthy tend to be eaten by women with healthier lifestyles and higher socioeconomic status, while some seemingly odd positive associations—such as those for Brussels sprouts, cauliflower and green peas—may simply reflect the contexts in which these vegetables are consumed, for example alongside high-fat meals. Spearman correlation analyses showed that many significant dietary factors are strongly intercorrelated: protein tracks closely with zinc, phosphorus and a dozen other nutrients, while vegetables correlate strongly with carotene and moderately with fibre and vitamin C. This web of correlations makes it statistically difficult to isolate the effect of any single food or nutrient. E-values for the significant findings ranged from 1.22 to 1.98, meaning an unmeasured confounder modestly associated with both diet and fracture risk could potentially explain away the observed associations.

The sensitivity analyses largely reinforced this cautious interpretation. Results were consistent across subgroups defined by smoking, exercise, hormone therapy, deprivation and baseline health, and remained so after excluding early follow-up years. In the least confounded subgroup—31,391 women with normal weight who had never smoked, drank only mildly and had never used hormone therapy—the directions of association held, though only vegetables, fibre and pasta retained conventional statistical significance, a pattern the authors attribute to reduced sample size rather than attenuation. Notably, alcohol told a cautionary tale: although overall intake showed a small inverse association, this reversed among regular drinkers, whose risk rose 10 percent per additional 10 grams per day, echoing Mendelian randomisation studies that find no protective effect of alcohol on fracture risk.

Even the traditional pillars of bone health did not escape scrutiny unscathed. Among dairy-related factors, only calcium and yoghurt were significantly associated with lower risk, at 6 percent per 300 milligrams and per 50 grams respectively, while recent genetic analyses have not supported causal roles for milk or circulating vitamin D. The authors conclude that confirmation is needed through replication in independent cohorts with different confounding structures, complementary causal inference methods and, where feasible, randomised trials. Until then, the study’s most defensible message is also its simplest: the overall pattern of a diet rich in vegetables, protein and whole foods, and light on fried potatoes and sugary drinks, tracks with stronger bones in later life—though whether the foods themselves, or the lives lived around them, deserve the credit remains an open question.

Subject of Research: Diet-wide associations between foods, nutrients and hip fracture risk in postmenopausal women

Article Title: Diet-wide association study (DWAS) of hip fracture risk in UK postmenopausal women: a prospective cohort study of 541,887 women with 27,318 incident cases over ~ 20 years

Article References: Tao, Y., Key, T. J., Reeves, G. K., Floud, S., Papier, K., & Tong, T. Y. N. (2026). Diet-wide association study (DWAS) of hip fracture risk in UK postmenopausal women: a prospective cohort study of 541,887 women with 27,318 incident cases over ~ 20 years. European Journal of Epidemiology. https://doi.org/10.1007/s10654-026-01466-3

Image Credits: AI Generated

DOI: 10.1007/s10654-026-01466-3

Keywords: hip fracture, diet-wide association study, nutritional epidemiology, postmenopausal women, Million Women Study, protein intake, vegetables, fizzy drinks, bone health, osteoporosis, prospective cohort study, confounding

The study, published in BMC Geriatrics by a team led by Yandie Wang and Fei Zeng of the Second Affiliated Hospital of Zhejiang University School of Medicine, took a qualitative approach to a problem that is usually measured only in bone mineral density scans. Osteoporosis is common after lung transplantation, driven by a convergence of factors: pre-transplant lung diseases such as chronic obstructive pulmonary disease and interstitial lung disease that already erode bone, the immunosuppressive drugs, particularly glucocorticoids, that patients must take for life, and the age-related bone loss that affects all older adults. The consequences are serious. Fragility fractures in transplant recipients are linked to frailty, disability, hospital readmission, and setbacks in functional recovery that can undo months of rehabilitation.

After discharge, the medical playbook for these patients is conceptually simple. They need to adhere to their medications, maintain adequate calcium intake and vitamin D supplementation, and perform weight-bearing and resistance exercises to slow further bone loss and reduce fracture risk. But knowing what should happen and understanding why it so often does not are two different questions, and it is the second question the researchers set out to answer. Between November 2025 and February 2026, they recruited twenty older lung transplant recipients with confirmed osteoporosis from a tertiary hospital in Zhejiang Province, using maximum variation purposive sampling to capture a range of experiences rather than a narrow, average patient.

The methodological backbone of the study was the Integrated Theory of Health Behavior Change, a framework that organizes health behavior into three domains: knowledge and beliefs, self-regulation skills and abilities, and social facilitation. The researchers used this theory to structure their semi-structured interviews and then applied directed content analysis to the transcripts, continuing recruitment until they reached code and meaning saturation, the point at which new interviews stopped producing new themes. Reporting followed the Consolidated Criteria for Reporting Qualitative Research checklist, a standard that helps readers judge the rigor of qualitative work. What emerged was a map of seven themes spread across the three domains, and together they paint a picture of self-management as a fragile system that can fail at multiple points.

The first domain, knowledge and beliefs, revealed a striking perceptual problem: osteoporosis was difficult for these patients to recognize and easy to deprioritize. Unlike rejection episodes or lung function decline, bone loss is silent. There is no breathlessness, no cough, no acute crisis to signal that the skeleton is weakening. In the hierarchy of threats that a transplant recipient must monitor, the invisible one loses. This perceptual invisibility meant that osteoporosis care competed poorly for attention against the demanding regimen of immunosuppression monitoring, infection vigilance, and pulmonary rehabilitation that dominates post-transplant life.

Compounding the priority problem, the researchers found that low confidence and negative self-appraisal constrained self-management. Patients who doubted their own capacity to manage yet another chronic condition tended to disengage, a pattern consistent with the self-efficacy literature across chronic disease. Yet the same domain contained a powerful counterweight: a sense of responsibility for preserving the benefits of the transplant. For many recipients, the gift of new lungs carried a moral weight, a duty to protect the outcome that donors and surgical teams had made possible. That sense of stewardship motivated them to persist with bone-protecting behaviors even when motivation from other sources flagged. It is a psychologically interesting finding, suggesting that framing osteoporosis care as part of protecting the transplant itself, rather than as a separate health task, could harness an existing motivational engine.

The second domain, self-regulation skills and abilities, exposed a structural bottleneck that the authors describe as task overload and limited capacity. Older transplant recipients are not managing one condition; they are managing a portfolio of them, each with its own medications, monitoring requirements, dietary considerations, and exercise prescriptions. When the total self-management workload exceeds a patient’s cognitive and physical capacity, something gives, and bone health, being silent and slow-moving, is a likely candidate. Against this, the study identified a genuine facilitator: patients who succeeded in organizing and adapting their osteoporosis self-management into everyday life, weaving calcium intake, supplements, and weight-bearing activity into existing routines rather than treating them as separate tasks, were better able to sustain the behaviors over time. The practical implication is that integration, not addition, is the design principle that works.

The third domain, social facilitation, may be the most actionable. The researchers found that multiple constraints in home-based support and resources hindered self-management. Older recipients living at home often lacked family members available or able to help, faced financial or logistical barriers to accessing care, and had limited contact with health professionals once the intensive post-transplant follow-up period receded. In contrast, multilevel support, spanning family caregivers, community resources, and accessible professional follow-up, facilitated sustained self-management. The word multilevel matters here: no single layer of support was sufficient on its own, but patients embedded in overlapping networks of practical help and professional oversight managed to maintain the regimen.

Taken together, the findings point to a conclusion that challenges the standard post-discharge model. The authors argue that support for these patients should extend beyond knowledge-based education, which assumes the problem is information, and instead combine coordinated, continuous, and tailored home-based guidance with family caregiver involvement and accessible professional follow-up. Management plans, they suggest, should be aligned with each recipient’s actual capacities and family caregiving circumstances, and osteoporosis management should be integrated into the established post-transplant routines that patients already perform reliably. In other words, the fix is not another leaflet; it is a redesign of how bone care is delivered so that it rides on the infrastructure patients already use.

The study has the inherent limits of qualitative work conducted at a single center in one Chinese province with twenty participants, and its themes describe experiences rather than quantify outcomes. But its value lies precisely in the granularity that only interviews can provide. Quantitative studies can tell us that adherence to bone-protecting regimens is poor in transplant recipients; this study explains the mechanics of that failure, from the invisibility of bone loss to the arithmetic of task overload to the absence of support at home. As transplant medicine continues to extend survival, the frontier is shifting from keeping patients alive to keeping them functional, and the skeleton, it turns out, is part of that frontier. For the growing population of older lung transplant recipients, the difference between a fragility fracture and continued independence may depend not on new drugs, but on whether the health system learns to build bone care into the fabric of daily life rather than leaving it as one more silent task on an already impossible list.

Subject of Research: Home-based osteoporosis self-management in older lung transplant recipients

Article Title: Barriers and facilitators to home-based osteoporosis self-management among older lung transplant recipients: a qualitative study

Article References: Wang, Y., Xie, M., Hao, F., Liang, J., Gu, P., Xu, A., & Zeng, F. (2026). Barriers and facilitators to home-based osteoporosis self-management among older lung transplant recipients: a qualitative study. BMC Geriatrics. https://doi.org/10.1186/s12877-026-08445-z

Image Credits: AI Generated

DOI: 10.1186/s12877-026-08445-z

Keywords: lung transplantation, osteoporosis, older adults, self-management, qualitative research, bone health, fracture risk, health behavior, caregiver support, post-transplant care, self-efficacy, BMC Geriatrics

The research team, led by Miriam T. Y. Leung of Monash University in collaboration with colleagues at the University of Eastern Finland, drew on the FINPARK cohort, a nationwide register-based dataset covering the entire Finnish population. The study included 11,051 people diagnosed with Parkinson’s disease between 2000 and 2009, each matched by age and sex to two comparison individuals without the disease, yielding 22,102 matched controls. By linking records from the Care Register for Healthcare, the Prescription Register, and Statistics Finland through each resident’s unique personal identification number, the researchers could track every dispensing of anti-osteoporosis medication, every hospital admission, and every death across an extraordinary fifteen-year window: five years before the Parkinson’s diagnosis and ten years after it.

The medications under scrutiny were the standard pharmacological arsenal against osteoporosis: bisphosphonates, the workhorse antiresorptive drugs that slow bone breakdown; denosumab, a monoclonal antibody that blocks the cells responsible for bone resorption; and calcitonin, an older hormone-based therapy that has largely fallen out of favor and was withdrawn from the Finnish market in 2012 due to limited efficacy. Annual prevalence was calculated as the proportion of cohort members who received at least one dispensing of any of these drugs in a given year, restricted to people who spent at least sixty days living in the community to allow realistic opportunity for pharmacy dispensing.

The first major finding was unexpected. Contrary to earlier reports suggesting that osteoporosis is chronically under-recognized in people with Parkinson’s, the Finnish data showed that medication use was actually higher among people with the disease than among matched controls. The divergence emerged surprisingly early, three full years before the formal diagnosis of Parkinson’s, when 3.62 percent of people who would later be diagnosed were receiving anti-osteoporosis therapy compared with 2.91 percent of controls. That gap widened dramatically after diagnosis, peaking four years in, when 8.67 percent of the Parkinson’s group were being treated versus just 4.73 percent of the comparison group, and it remained elevated through the end of follow-up.

Why would bone-protecting drugs appear in the records of people three years before anyone has diagnosed their Parkinson’s? The authors point to the prodromal phase of the disease, the period when early motor and non-motor symptoms, including subtle balance problems and increased fall risk, begin to manifest before the classic diagnostic criteria are met. Their own previous work in the same cohort showed that hip fracture risk is already elevated in the years preceding diagnosis. Fractures themselves may also act as a trigger: a person who breaks a bone is more likely to be screened for osteoporosis and started on treatment, and the heightened dispensing observed after hip fractures in this study supports exactly that pathway. Reduced mobility and greater use of psychotropic medications, both documented in this cohort years before diagnosis, further compound the fracture risk.

The second key finding concerns what happens after a hip fracture, the moment when secondary prevention matters most. Among the 1,475 people with Parkinson’s and 1,371 controls who suffered an incident hip fracture during follow-up, treatment patterns were strikingly similar between the two groups. Anti-osteoporosis dispensing peaked within the first year after the fracture, reaching 20.3 percent in the Parkinson’s group and 21.0 percent in the controls, roughly one in five patients. By five years after the fracture, prevalence had settled to around 14 to 16 percent in both groups. In other words, having Parkinson’s neither helped nor hindered access to post-fracture pharmacological prevention, a result that directly contradicts the under-treatment narrative from smaller earlier studies.

Yet the absolute numbers tell a more sobering story. A one-in-five treatment rate after a fragility fracture leaves four in five patients without the therapy that could prevent the next break, and the Finnish figures, while comparable to other Nordic countries, fall far short of the more than 50 percent post-fracture treatment prevalence reported in the United Kingdom. The authors attribute part of this gap to national guideline differences. The Finnish Current Care Guideline on hip fracture recommends anti-osteoporosis medications only for patients expected to regain independent mobility, explicitly excluding those anticipated to remain bedbound, and it places heavy emphasis on fall-risk management, noting that ninety percent of hip fractures result from a fall. Multidisciplinary fracture liaison services, which systematically assess every fracture patient, have been shown elsewhere to raise both treatment rates and fall-prevention efforts, and the study suggests they could play a valuable role in Finland.

Sex differences added another layer of complexity. Women, whether with or without Parkinson’s, received anti-osteoporosis medications at consistently higher rates than men throughout follow-up, reflecting the earlier onset of postmenopausal bone loss. Among women with Parkinson’s, treatment prevalence peaked at 15.5 percent four years after diagnosis, then declined, a pattern consistent with postmenopausal osteoporosis being treated early and later paused. Men with Parkinson’s showed the opposite trajectory, with use climbing slowly to a peak of just 3.16 percent eight years after diagnosis. After hip fracture, women again led with 25.6 percent treated within a year versus 12.2 percent of men, but men’s post-fracture treatment remained elevated for up to five years while women’s declined. The gradual decline in bisphosphonate use beyond four years after diagnosis may reflect not only poor adherence, a well-documented problem with oral bisphosphonates, but also deliberate clinical decisions: guidelines recommend a drug holiday of one to two years after three to five years of bisphosphonate therapy in lower-risk patients to minimize long-term adverse effects.

The study’s strengths lie in its scale and completeness. Nationwide registers minimize selection bias, the fifteen-year follow-up captures the full arc from prodrome to late disease, and the prediagnostic window, never examined before in this context, proved scientifically critical given that fracture risk is already elevated before diagnosis. The limitations are equally instructive: over-the-counter vitamin D and calcium, dispensed without prescription, were invisible to the database; no bone mineral density measurements or blood tests were available to judge whether treatment matched individual bone health; and medications administered intravenously in hospitals, such as zoledronic acid, could not be captured. These gaps mean the true extent of bone-protective care may be somewhat higher than the dispensing records suggest.

The takeaway for clinicians and researchers is that the problem in Parkinson’s may not be unequal access to osteoporosis drugs, but rather that drugs alone are not enough to counteract a risk that is doubled at its source. With sustained fracture risk extending a full decade after diagnosis, the authors argue that additional preventive measures, above all regular and systematic review of fall risk, must run alongside pharmacotherapy. As Parkinson’s prevalence continues its steep global climb, protecting the skeletons of the people it affects may demand a shift from reactive treatment after the break to proactive, multidisciplinary prevention before the fall ever happens.

Subject of Research: Anti-osteoporosis medication use in persons with and without Parkinson's disease in Finland

Article Title: Anti-osteoporosis medications in persons with and without Parkinson disease in Finland

Article References: Leung, M. T. Y., Lamidi, M.-L., Tiihonen, M., Hartikainen, S., Bell, J. S., Turner, J. P., & Tolppanen, A.-M. (2026). Anti-osteoporosis medications in persons with and without Parkinson disease in Finland. Archives of Osteoporosis, 21(1), Article 143. https://doi.org/10.1007/s11657-026-01780-z

Image Credits: AI Generated

DOI: 10.1007/s11657-026-01780-z

Keywords: Parkinson's disease, osteoporosis, hip fracture, bisphosphonates, denosumab, anti-osteoporosis medications, Finland, nationwide cohort, fracture prevention, fall risk, secondary prevention, bone health